Herbs (Global Traditional) · African
Devil's Claw (Harpagophytum zeyheri) (Harpagophytum zeyheri)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Devil's claw (Harpagophytum zeyheri) is a medicinal plant containing harpagoside as its primary bioactive compound. It reduces inflammation and pain by inhibiting inflammatory mediators like TNF-alpha and cyclooxygenase enzymes.
Devil's Claw refers to the secondary root tubers of Harpagophytum procumbens or H. zeyheri, perennial desert herbs native to southern Africa, particularly Namibia, Botswana, and South Africa. The tuberous roots are harvested, dried, and processed into extracts, powders, or teas via aqueous or ethanol-based extraction methods, typically standardized to contain 2-5% harpagoside content.
A 2007 systematic review identified 14 trials on Devil's Claw for osteoarthritis, with higher-quality RCTs showing pain reduction but suffering from methodological flaws including inadequate blinding and small sample sizes (often <100 participants). A 2002 analysis found that extracts containing >50 mg/day harpagoside alleviated OA pain across trials with 40-90 participants over 4-8 weeks, while a 12-week study (n=75) using Teltonal extract showed significant pain relief for hip/knee osteoarthritis.
Dry extracts standardized to 50-100 mg harpagoside/day (effective dose in OA trials). Powdered root: 2400-6645 mg/day. Liquid extracts (1:1): 480-1030 mg/day. Treatment duration in studies: 4-12 weeks. Consult a healthcare provider before starting any new supplement.
Devil's Claw (Harpagophytum zeyheri) is not consumed as a food source for macronutrient value but is valued for its bioactive phytochemical profile. **Primary bioactive compounds:** • Iridoid glycosides — the principal active class, including harpagoside (typically 0.5–3.0% in dried tuber, though H. zeyheri generally contains lower concentrations than H. procumbens, often 0.5–1.2%), harpagide (~0.1–0.5%), and procumbide (~0.1–0.3%). Harpagoside is considered the primary marker compound responsible for anti-inflammatory and analgesic activity. • 8-p-coumaroylharpagide — an iridoid ester present in notable quantities, sometimes used as a distinguishing marker for H. zeyheri versus H. procumbens. • Acteoside (verbascoside) — a phenylpropanoid glycoside with demonstrated antioxidant activity, present at approximately 0.2–1.0% of dried root weight. • Free phenolic acids — including caffeic acid, cinnamic acid, and chlorogenic acid, contributing to overall antioxidant capacity. **Secondary metabolites:** • Flavonoids — including luteolin and kaempferol glycosides in trace to moderate amounts. • Phytosterols — including beta-sitosterol (~0.01–0.05%), with modest anti-inflammatory contributions. • Triterpenes — including oleanolic acid and ursolic acid in minor concentrations. • Quinone compounds — including harpagoquinone, present in small amounts. **Sugars and polysaccharides:** • Stachyose and other oligosaccharides (~40–50% of dried tuber by weight), along with water-soluble polysaccharides that make up a substantial portion of the secondary tuber mass. **Mineral content (approximate per 100 g dried tuber):** • Calcium: 500–800 mg • Iron: 5–12 mg • Magnesium: 150–300 mg • Potassium: 600–1000 mg • Phosphorus: 100–200 mg • Trace minerals: manganese, zinc, copper, and selenium in small quantities. **Fiber:** Crude fiber content approximately 8–15% of dried tuber weight. **Protein:** Low, approximately 4–7% of dried tuber weight. **Fat:** Very low, approximately 0.5–1.5%. **Bioavailability notes:** Harpagoside has moderate oral bioavailability but undergoes significant first-pass hepatic metabolism and partial hydrolysis in the gastrointestinal tract to release harpagogenin (the aglycone), which retains biological activity. Standardized extracts (typically dosed to deliver 50–100 mg harpagoside daily in clinical studies) show measurable plasma levels within 1–2 hours. The aqueous and ethanolic extraction methods significantly affect iridoid glycoside yield; ethanol-water (30–60%) mixtures generally optimize harpagoside recovery. H. zeyheri is often noted to have a somewhat different iridoid glycoside ratio compared to H. procumbens, with relatively higher 8-p-coumaroylharpagide and lower harpagoside, which may influence comparative clinical efficacy.
Devil's claw's harpagoside and other iridoid glycosides inhibit pro-inflammatory cytokines including TNF-alpha, interleukin-1β, and interleukin-6. The compounds suppress cyclooxygenase-2 (COX-2) and lipoxygenase pathways, reducing prostaglandin and leukotriene production. This dual anti-inflammatory action decreases joint inflammation and associated pain signaling.
Four double-blind RCTs demonstrate moderate evidence for osteoarthritis pain reduction, with participants experiencing 20-25% pain score improvements over 8-12 weeks. Multiple trials show enhanced mobility in musculoskeletal conditions using standardized extracts containing 50-100mg harpagoside daily. Study limitations include small sample sizes (30-89 participants) and variable extraction methods. Evidence quality is considered moderate due to methodological constraints but consistently positive outcomes.
Devil's claw is generally well-tolerated with mild gastrointestinal upset reported in 5-10% of users. It may enhance warfarin's anticoagulant effects and should be avoided with blood-thinning medications. Contraindicated in individuals with peptic ulcers, gallstones, or cardiac arrhythmias. Safety during pregnancy and lactation is unknown, requiring avoidance in these populations.
